Business
Interim report 2025/26 - Organic growth despite challenges in the North American market
ANNOUNCEMENT NO. 299 4 February 2026 Interim report for the first half of 2025/26 Organic growth despite challenges in the North American market Martin Helbo Behrens, CEO: In the first half of 2025/26, our revenue was up 3% measured in local currencies, while in Danish kroner it was down to DKK 249.0 million, a year-on-year decrease of 1%. Despite this, EBITDA and the EBITDA margin showed a slight increase. Revenue was affected by a sharp slowdown in US demand, as many of our customers in the US
About this update from Chemometec A/s
[{"type":"image","alt":"Chemometec A/S","displaySize":"","headline":null,"caption":"Chemometec A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":210,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/fb7f647883e7e37b706ad984bdd29198"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4NfO27rPrtZqtUz4kabB5g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fb7f647883e7e37b706ad984bdd29198","width":210,"height":87}},"lazy":false},{"type":"text","content":"ANNOUNCEMENT NO. 299","length":20,"tagName":"p"},{"type":"text","content":"4 February 2026","length":15,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"Interim report for the first half of 2025/26","length":44,"tagName":"p"},{"type":"text","content":"Organic growth despite challenges in the North American market","length":62,"tagName":"p"},{"type":"text","content":"Martin Helbo Behrens, CEO: In the first half of 2025/26, our revenue was up 3% measured in local currencies, while in Danish kroner it was down to DKK 249.0 million, a year-on-year decrease of 1%. Despite this, EBITDA and the EBITDA margin showed a slight increase. Revenue was affected by a sharp slowdown in US demand, as many of our customers in the USA were severely impacted by the historically long government shutdown in the second quarter of 2025/26. Quite exceptionally, our revenue in November was therefore some DKK 20 million lower than last November. In spite of this, we are satisfied with sales of our XcytoMatic instruments, which showed 60% organic growth compared with the year-earlier period. ","length":711,"tagName":"p"},{"type":"text","content":"Although US market trends remain uncertain in the short term, cell and gene therapy is seeing strong momentum with significant investments by large US market players in particular, making the US cell and gene therapy market an attractive area of potential growth for us.","length":270,"tagName":"p"},{"type":"text","content":"To support future growth, we stepped up our efforts throughout 2025 to establish new partnerships that enable us to offer our customers more comprehensive workflow automation solutions. Our main focus was on partnerships with European companies with customers in the bioprocessing segment, particularly in Europe and Asia.","length":322,"tagNa...